Michael Campbell to Immunotherapy
This is a "connection" page, showing publications Michael Campbell has written about Immunotherapy.
Connection Strength
0.238
-
Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precis Oncol. 2025 Jun; 9:e2400776.
Score: 0.188
-
Liu NM, Sholevar CJ, Karimzadeh M, Uppuluri J, Van Dongen C, Graves CE, Campbell MJ, Zamora AE, Judge SJ, Canter RJ. The Immune Biology of the Adrenal Gland Microenvironment and Its Role in Metastatic Progression. Int J Mol Sci. 2026 Jan 23; 27(3).
Score: 0.049